LABELS · 4b984e6f-72ac-4fdc-e063-6394a90af105

Cimzia

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-02-24
Captured: 2026-09-09T23:37:47.659725+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before CIMZIA use and during therapy. Treatment for latent infection should be initiated prior to CIMZIA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member [see Warnings and Precautions (5.2) ]. WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens ( 5.1 ). CIMZIA should be discontinued if a patient develops a serious infection or sepsis ( 5.1 ). Perform test for latent TB; if positive, start treatment for TB prior to starting CIMZIA ( 5.1 ). Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member ( 5.2 ).

Indications and usage: exact source text

1 INDICATIONS AND USAGE CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) 1.1 Crohn's Disease CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.4 Psoriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ] 1.6 Non-radiographic Axial Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see Clinical Studies (14.6) ]. 1.7 Plaque Psoriasis CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy [see Clinical Studies (14.7) ]

Full extracted label fields

application numbers

BLA125160

boxed warning exact

WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. CIMZIA should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before CIMZIA use and during therapy. Treatment for latent infection should be initiated prior to CIMZIA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member [see Warnings and Precautions (5.2) ]. WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens ( 5.1 ). CIMZIA should be discontinued if a patient develops a serious infection or sepsis ( 5.1 ). Perform test for latent TB; if positive, start treatment for TB prior to starting CIMZIA ( 5.1 ). Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member ( 5.2 ).

brand names

Cimzia

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

generic names

CERTOLIZUMAB PEGOL

4b984e6f-72ac-4fdc-e063-6394a90af105

indications and usage exact

1 INDICATIONS AND USAGE CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) 1.1 Crohn's Disease CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.4 Psoriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ] 1.6 Non-radiographic Axial Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see Clinical Studies (14.6) ]. 1.7 Plaque Psoriasis CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy [see Clinical Studies (14.7) ]

indications and usage tables exact

is original packager

true

manufacturer names

UCB, Inc.

matched search terms

tumor

package ndcs

50474-700-62
50474-700-61
50474-710-79
50474-710-80
50474-710-81
50474-750-10

product ndcs

50474-700
50474-710
50474-750

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

795081
795085
849597
849599
2724369
2724370
2724371
2724372

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00300.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 757
end exclusive: true
exact text: 1 INDICATIONS AND USAGE CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 0

current approval status

not_reconciled

duplicate text group

dup-03cb384724d04f2ca770

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-d31a1ea024c0475ae797

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 31

qualifier mentions

context exact
oms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an
kind
age
polarity
not_inferred
span
end
185
end exclusive
true
exact text
adult patients
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
171
context exact
quate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1
kind
age
polarity
not_inferred
span
end
316
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
310
context exact
yarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active p
kind
age
polarity
not_inferred
span
end
478
end exclusive
true
exact text
2 years of age
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
464
context exact
) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis.
kind
age
polarity
not_inferred
span
end
524
end exclusive
true
exact text
adult patients
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
510

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 557
end exclusive: true
exact text: 1 INDICATIONS AND USAGE CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis.
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1071
end exclusive: true
exact text: toid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) 1.1 Crohn's Disease CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 358

current approval status

not_reconciled

duplicate text group

dup-c7e78152cc4fff574d1e

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-ebc8491898fadac2ace8

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 81
end exclusive: true
exact text: is a tumor necrosis factor (TNF) blocker indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 31

qualifier mentions

context exact
( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adu
kind
age
polarity
not_inferred
span
end
585
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
579
context exact
lts with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with o
kind
age
polarity
not_inferred
span
end
648
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
642
context exact
s with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates
kind
age
polarity
not_inferred
span
end
766
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
760

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 871
end exclusive: true
exact text: ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 )
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 558

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 3 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1318
end exclusive: true
exact text: aphic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) 1.1 Crohn's Disease CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indica
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 672

current approval status

not_reconciled

duplicate text group

dup-f4289c61f31d0d256dd6

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-293742ea84f06068d5a5

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 911
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 899

qualifier mentions

context exact
oms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an
kind
age
polarity
not_inferred
span
end
1014
end exclusive
true
exact text
adult patients
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1000

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1118
end exclusive: true
exact text: 1.1 Crohn's Disease CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 872

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 4 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1453
end exclusive: true
exact text: ucing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.4 Psoriatic
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 919

current approval status

not_reconciled

duplicate text group

dup-3ced429e6872c2b4b081

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-2385d2c99d4e70874896

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 1163
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1151

qualifier mentions

context exact
eumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA
kind
age
polarity
not_inferred
span
end
1191
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1185

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1253
end exclusive: true
exact text: 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA).
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1119

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 5 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1638
end exclusive: true
exact text: ase who have had an inadequate response to conventional therapy. 1.2 Rheumatoid Arthritis CIMZIA is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.4 Psoriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1054

current approval status

not_reconciled

duplicate text group

dup-dfa8a91fa80e5e6f0a8e

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-512c27e63a923159f229

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 1321
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1309

qualifier mentions

context exact
yarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
1427
end exclusive
true
exact text
2 years of age
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1413

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1438
end exclusive: true
exact text: 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1254

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 6 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1757
end exclusive: true
exact text: rthritis (RA). 1.3 Polyarticular Juvenile Idiopathic Arthritis CIMZIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.4 Psoriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ] 1.6 Non-radiographic Axial Spondyloarthritis CIMZIA
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1239

current approval status

not_reconciled

duplicate text group

dup-2dcebbad33084bcc6a45

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-7431202f859fcfefd105

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 1482
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1470

qualifier mentions

context exact
soriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).
kind
age
polarity
not_inferred
span
end
1518
end exclusive
true
exact text
adult patients
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1504

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1557
end exclusive: true
exact text: 1.4 Psoriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA).
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1439

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1904
end exclusive: true
exact text: cular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older. 1.4 Psoriatic Arthritis CIMZIA is indicated for the treatment of adult patients with active psoriatic arthritis (PsA). 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ] 1.6 Non-radiographic Axial Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1358

current approval status

not_reconciled

duplicate text group

dup-38dfc94d437ae188071a

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-1f21b85118ee771999ed

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 1604
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1592

qualifier mentions

context exact
losing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Stud
kind
age
polarity
not_inferred
span
end
1632
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1626

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1704
end exclusive: true
exact text: 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ]
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1558

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2130
end exclusive: true
exact text: dult patients with active psoriatic arthritis (PsA). 1.5 Ankylosing Spondylitis CIMZIA is indicated for the treatment of adults with active ankylosing spondylitis (AS). [see Clinical Studies (14.5) ] 1.6 Non-radiographic Axial Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see Clinical Studies (14.6) ]. 1.7 Plaque Psoriasis CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy [see Clinical Studies (14.7
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1505

current approval status

not_reconciled

duplicate text group

dup-a988e33e623908e2dcc3

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-f010bf78455148c93783

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 1769
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1757

qualifier mentions

context exact
Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-ax
kind
age
polarity
not_inferred
span
end
1797
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1791

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 1930
end exclusive: true
exact text: 1.6 Non-radiographic Axial Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see Clinical Studies (14.6) ].
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1705

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

BLA125160

brand names

Cimzia

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2133
end exclusive: true
exact text: Spondyloarthritis CIMZIA is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation [see Clinical Studies (14.6) ]. 1.7 Plaque Psoriasis CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy [see Clinical Studies (14.7) ]
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1731

current approval status

not_reconciled

duplicate text group

dup-6bbc65e2e0ab6a3ae087

extraction review status

automated_candidate_pending_source_review

generic names

CERTOLIZUMAB PEGOL

ind-span-b6d8e958e5125860dbc2

label id

4b984e6f-72ac-4fdc-e063-6394a90af105

positive predicate support span

end: 1971
end exclusive: true
exact text: is indicated
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1959

qualifier mentions

context exact
7 Plaque Psoriasis CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are cand
kind
age
polarity
not_inferred
span
end
1999
end exclusive
true
exact text
adults
label id
4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start
1993

regulatory links

schema version

0.1.0

source batch sha256

bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e

source defined aliases

source span

end: 2133
end exclusive: true
exact text: 1.7 Plaque Psoriasis CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy [see Clinical Studies (14.7) ]
label id: 4b984e6f-72ac-4fdc-e063-6394a90af105
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8cc6d33dceb8bec7862739132a63d0f0bbbec84705b4a62ef39e94ad47053baa
start: 1931

source url

https://api.fda.gov/drug/label.json?search=id%3A%224b984e6f-72ac-4fdc-e063-6394a90af105%22

spl effective date

2026-02-24

spl set id

b4c2c9dc-a0bb-4d64-a667-a67ebe88392d

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice